TY - JOUR
T1 - Perspective for Precision Medicine for Tuberculosis
AU - Lange, Christoph
AU - Aarnoutse, Rob
AU - Chesov, Dumitru
AU - van Crevel, Reinout
AU - Gillespie, Stephen H.
AU - Grobbel, Hans Peter
AU - Kalsdorf, Barbara
AU - Kontsevaya, Irina
AU - van Laarhoven, Arjan
AU - Nishiguchi, Tomoki
AU - Mandalakas, Anna
AU - Merker, Matthias
AU - Niemann, Stefan
AU - Köhler, Niklas
AU - Heyckendorf, Jan
AU - Reimann, Maja
AU - Ruhwald, Morten
AU - Sanchez-Carballo, Patricia
AU - Schwudke, Dominik
AU - Waldow, Franziska
AU - DiNardo, Andrew R.
N1 - Funding Information:
The publication of this article was supported by the Open Access Publication Fund of the Leibniz Association.
Publisher Copyright:
© Copyright © 2020 Lange, Aarnoutse, Chesov, van Crevel, Gillespie, Grobbel, Kalsdorf, Kontsevaya, van Laarhoven, Nishiguchi, Mandalakas, Merker, Niemann, Köhler, Heyckendorf, Reimann, Ruhwald, Sanchez-Carballo, Schwudke, Waldow and DiNardo.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/10/8
Y1 - 2020/10/8
N2 - Tuberculosis is a bacterial infectious disease that is mainly transmitted from human to human via infectious aerosols. Currently, tuberculosis is the leading cause of death by an infectious disease world-wide. In the past decade, the number of patients affected by tuberculosis has increased by ~20 percent and the emergence of drug-resistant strains of Mycobacterium tuberculosis challenges the goal of elimination of tuberculosis in the near future. For the last 50 years, management of patients with tuberculosis has followed a standardized management approach. This standardization neglects the variation in human susceptibility to infection, immune response, the pharmacokinetics of drugs, and the individual duration of treatment needed to achieve relapse-free cure. Here we propose a package of precision medicine-guided therapies that has the prospect to drive clinical management decisions, based on both host immunity and M. tuberculosis strains genetics. Recently, important scientific discoveries and technological advances have been achieved that provide a perspective for individualized rather than standardized management of patients with tuberculosis. For the individual selection of best medicines and host-directed therapies, personalized drug dosing, and treatment durations, physicians treating patients with tuberculosis will be able to rely on these advances in systems biology and to apply them at the bedside.
AB - Tuberculosis is a bacterial infectious disease that is mainly transmitted from human to human via infectious aerosols. Currently, tuberculosis is the leading cause of death by an infectious disease world-wide. In the past decade, the number of patients affected by tuberculosis has increased by ~20 percent and the emergence of drug-resistant strains of Mycobacterium tuberculosis challenges the goal of elimination of tuberculosis in the near future. For the last 50 years, management of patients with tuberculosis has followed a standardized management approach. This standardization neglects the variation in human susceptibility to infection, immune response, the pharmacokinetics of drugs, and the individual duration of treatment needed to achieve relapse-free cure. Here we propose a package of precision medicine-guided therapies that has the prospect to drive clinical management decisions, based on both host immunity and M. tuberculosis strains genetics. Recently, important scientific discoveries and technological advances have been achieved that provide a perspective for individualized rather than standardized management of patients with tuberculosis. For the individual selection of best medicines and host-directed therapies, personalized drug dosing, and treatment durations, physicians treating patients with tuberculosis will be able to rely on these advances in systems biology and to apply them at the bedside.
UR - http://www.scopus.com/inward/record.url?scp=85094095750&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2020.566608
DO - 10.3389/fimmu.2020.566608
M3 - Scientific review articles
C2 - 33117351
AN - SCOPUS:85094095750
SN - 1664-3224
VL - 11
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 566608
ER -